Skip to main content
Erschienen in: Osteoporosis International 10/2012

01.10.2012 | Position Paper

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges

verfasst von: D. Bauer, J. Krege, N. Lane, E. Leary, C. Libanati, P. Miller, G. Myers, S. Silverman, H. W. Vesper, D. Lee, M. Payette, S. Randall

Erschienen in: Osteoporosis International | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Summary

This position paper reviews how the National Bone Health Alliance (NBHA) will execute a project to help assure health professionals of the clinical utility of bone turnover markers; the current clinical approaches concerning osteoporosis and the status and use of bone turnover markers in the USA; the rationale for focusing this effort around two specific bone turnover markers; the need to standardize bone marker sample collection procedures, reference ranges, and bone turnover marker assays in clinical laboratories; and the importance of harmonization for future research of bone turnover markers.

Introduction

Osteoporosis is a major global health problem, with the prevalence and incidence of osteoporosis for at-risk populations estimated to be 44 million Americans. The potential of bone markers as an additional tool for health care professionals to improve patient outcomes and impact morbidity and mortality is crucial in providing better health care and addressing rising health care costs. This need to advance the field of bone turnover markers has been recognized by a number of organizations, including the International Osteoporosis Foundation (IOF), National Osteoporosis Foundation, International Federation of Clinical Chemistry, and Laboratory Medicine (IFCC), and the NBHA.

Methods

This position paper elucidates how this project will standardize bone turnover marker sample collection procedures in the USA, establish a USA reference range for one bone formation (serum procollagen type I N propeptide, s-PINP) and one bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) marker, and standardize bone turnover marker assays used in clinical laboratories. This effort will allow clinicians from the USA to have confidence in their use of bone turnover markers to help monitor osteoporosis treatment and assess future fracture risk. This project builds on the recommendations of the IOF/IFCC Bone Marker Standards Working Group by developing USA reference standards for s-PINP and s-CTX, the markers identified as most promising for use as reference markers.

Results

The goals of this project will be realized through the NBHA and will include its governmental, academic, for-profit, and non-profit sector stakeholders as well as major academic and commercial laboratories. Upon completion, a parallel effort will be pursued to make bone turnover marker measurements reliable and accepted by all health care professionals for facilitating treatment decisions and ultimately be reimbursed by all health insurance payers.

Conclusions

Successful completion of this project will help assure health professionals from the USA of the clinical utility of bone turnover markers and ties in with the parallel effort of the IOF/IFCC to develop worldwide bone turnover reference ranges.
Literatur
1.
Zurück zum Zitat NOF (2010) NOF clinician’s guide to prevention and treatment of osteoporosis. NOF, Washington NOF (2010) NOF clinician’s guide to prevention and treatment of osteoporosis. NOF, Washington
2.
Zurück zum Zitat Schafer AL L, Vittinghoff E, Ramachandran R, Mahmoud N, Bauer DC (2010) Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int 21:439–455PubMedCrossRef Schafer AL L, Vittinghoff E, Ramachandran R, Mahmoud N, Bauer DC (2010) Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int 21:439–455PubMedCrossRef
3.
Zurück zum Zitat Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis Int 22(2):391–420CrossRef Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis Int 22(2):391–420CrossRef
4.
Zurück zum Zitat Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type 1 collagen (serum s-CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol and fasting. Bone 31:57–61PubMedCrossRef Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type 1 collagen (serum s-CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol and fasting. Bone 31:57–61PubMedCrossRef
5.
Zurück zum Zitat Clowes JA, Hannon RA, Yap TA, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886–890PubMedCrossRef Clowes JA, Hannon RA, Yap TA, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886–890PubMedCrossRef
6.
Zurück zum Zitat Rifai N, Cooper GR, Brown WV, Friedewald W, Havel RJ, Myers GL, Warnick GR (2004) Clinical chemistry journal has contributed to progress in lipid and lipoprotein testing for fifty years. Clin Chem 50:1861–1870PubMedCrossRef Rifai N, Cooper GR, Brown WV, Friedewald W, Havel RJ, Myers GL, Warnick GR (2004) Clinical chemistry journal has contributed to progress in lipid and lipoprotein testing for fifty years. Clin Chem 50:1861–1870PubMedCrossRef
7.
Zurück zum Zitat Little RR, Rohlfing CL, Sacks DB, National Glycohemoglobin Standardization Program (NGSP) Steering Committee (2011) Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 57:205–214PubMedCrossRef Little RR, Rohlfing CL, Sacks DB, National Glycohemoglobin Standardization Program (NGSP) Steering Committee (2011) Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 57:205–214PubMedCrossRef
9.
Zurück zum Zitat Miller WG, Myers GL, Gantzer LM, Kahn SE, Schönbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Lo SF, Nübling CM, Sturgeon CM (2011) Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 57:1108–1117CrossRef Miller WG, Myers GL, Gantzer LM, Kahn SE, Schönbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Lo SF, Nübling CM, Sturgeon CM (2011) Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 57:1108–1117CrossRef
15.
Zurück zum Zitat Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R (2008) Establishing a reference range for bone turnover markers in young, healthy women. Bone 42:623–630PubMedCrossRef Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R (2008) Establishing a reference range for bone turnover markers in young, healthy women. Bone 42:623–630PubMedCrossRef
16.
Zurück zum Zitat Glover S, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley J, Black D, Delmas P, Eastell R (2009) Establishing a reference interval for bone turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA. J Bone Miner Res 24:389–397PubMedCrossRef Glover S, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley J, Black D, Delmas P, Eastell R (2009) Establishing a reference interval for bone turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA. J Bone Miner Res 24:389–397PubMedCrossRef
17.
Zurück zum Zitat de Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E, Rosenberg E, Reitz RE (2007) A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40:1222–1230PubMedCrossRef de Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E, Rosenberg E, Reitz RE (2007) A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40:1222–1230PubMedCrossRef
18.
Zurück zum Zitat Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, Dimunno O, Frediani B, Rossini M (2008) Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 82:341–347PubMedCrossRef Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, Dimunno O, Frediani B, Rossini M (2008) Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 82:341–347PubMedCrossRef
19.
Zurück zum Zitat Cavalier E, Delanaye P (2009) Letter to the editor: Defining a “reference population”: no easy task. JBMR 24:1638CrossRef Cavalier E, Delanaye P (2009) Letter to the editor: Defining a “reference population”: no easy task. JBMR 24:1638CrossRef
20.
Zurück zum Zitat Eastell R, Glover SJ, Gall M, Schoenborn-Kellenberger O, Garnero P, Black D (2009) Defining a “reference population”: no easy task. JBMR 24:1639CrossRef Eastell R, Glover SJ, Gall M, Schoenborn-Kellenberger O, Garnero P, Black D (2009) Defining a “reference population”: no easy task. JBMR 24:1639CrossRef
21.
Zurück zum Zitat Linnet K (1987) Two-stage transformation systems for normalization of reference distributions evaluated. Vlin Vhrm 33:381–386 Linnet K (1987) Two-stage transformation systems for normalization of reference distributions evaluated. Vlin Vhrm 33:381–386
22.
Zurück zum Zitat Baim S, Miller PD (2009) Perspective: assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 24:561–573PubMedCrossRef Baim S, Miller PD (2009) Perspective: assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 24:561–573PubMedCrossRef
23.
Zurück zum Zitat Keaveny TM, Kopperdahl DL, Melton LJ III, Hoffman PF, Amin S, Riggs BL, Khosla S (2010) Age-dependence of femoral neck strength in white women and men. J Bone Miner Res 25(5):994–1001PubMed Keaveny TM, Kopperdahl DL, Melton LJ III, Hoffman PF, Amin S, Riggs BL, Khosla S (2010) Age-dependence of femoral neck strength in white women and men. J Bone Miner Res 25(5):994–1001PubMed
24.
Zurück zum Zitat Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung MR, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, IOF-IFCC Bone Markers Standard Working Group (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420PubMedCrossRef Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung MR, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, IOF-IFCC Bone Markers Standard Working Group (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420PubMedCrossRef
25.
Zurück zum Zitat Melton LJ III, Khosla S, Atkinson EJ, O’Fallon WM, Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083–1091PubMedCrossRef Melton LJ III, Khosla S, Atkinson EJ, O’Fallon WM, Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083–1091PubMedCrossRef
26.
Zurück zum Zitat Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536PubMedCrossRef Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536PubMedCrossRef
27.
Zurück zum Zitat Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20:1813–1819PubMedCrossRef Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20:1813–1819PubMedCrossRef
28.
Zurück zum Zitat Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporosis Int 11(Suppl 6):S55–S65CrossRef Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporosis Int 11(Suppl 6):S55–S65CrossRef
29.
Zurück zum Zitat Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–1538PubMedCrossRef Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–1538PubMedCrossRef
30.
Zurück zum Zitat Ivaska KK, Gerdhem P, Vaananen HK, Akesson K, Obrant KJ (2010) Bone turnover markers and prediction of fracture: a prospective follow-up study of 1,040 elderly women for a mean of 9 years. J Bone Miner Res 25:393–403PubMedCrossRef Ivaska KK, Gerdhem P, Vaananen HK, Akesson K, Obrant KJ (2010) Bone turnover markers and prediction of fracture: a prospective follow-up study of 1,040 elderly women for a mean of 9 years. J Bone Miner Res 25:393–403PubMedCrossRef
31.
Zurück zum Zitat Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE, Orwoll E (2009) Osteoporotic fractures in men (MrOs) Research Group. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOs Study. J Bone Miner Res 24(12):2032–2038PubMedCrossRef Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE, Orwoll E (2009) Osteoporotic fractures in men (MrOs) Research Group. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOs Study. J Bone Miner Res 24(12):2032–2038PubMedCrossRef
32.
Zurück zum Zitat Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103PubMedCrossRef Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103PubMedCrossRef
33.
Zurück zum Zitat Recker R, Stakkestad JA, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:89–93CrossRef Recker R, Stakkestad JA, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:89–93CrossRef
34.
Zurück zum Zitat Papapolpous S, Schimmer RC (2007) Changes in bone remodeling and anti-fracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 66(7):853–858 Papapolpous S, Schimmer RC (2007) Changes in bone remodeling and anti-fracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 66(7):853–858
35.
Zurück zum Zitat Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRef Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRef
36.
Zurück zum Zitat Christiansen C, Riis BJ, Rodbro P (1987) Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105–1108PubMedCrossRef Christiansen C, Riis BJ, Rodbro P (1987) Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105–1108PubMedCrossRef
37.
Zurück zum Zitat Lenora J, Ivaska KK, Obrant KJ, Gerdhem P (2007) Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 18:1297–1305PubMedCrossRef Lenora J, Ivaska KK, Obrant KJ, Gerdhem P (2007) Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 18:1297–1305PubMedCrossRef
38.
Zurück zum Zitat Rogers A, Hannon RA, Eastell R (2000) Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 15:1398–1404PubMedCrossRef Rogers A, Hannon RA, Eastell R (2000) Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 15:1398–1404PubMedCrossRef
39.
Zurück zum Zitat Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762–2767PubMedCrossRef Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762–2767PubMedCrossRef
40.
Zurück zum Zitat Hannon RA, Bluhmson A, Naylor KE, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy. J Bone Miner Res 13:1124–1133PubMedCrossRef Hannon RA, Bluhmson A, Naylor KE, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy. J Bone Miner Res 13:1124–1133PubMedCrossRef
41.
Zurück zum Zitat Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS (2005) Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52:667–674PubMedCrossRef Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS (2005) Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52:667–674PubMedCrossRef
42.
Zurück zum Zitat Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244PubMedCrossRef Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244PubMedCrossRef
43.
Zurück zum Zitat Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368PubMedCrossRef Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368PubMedCrossRef
44.
Zurück zum Zitat Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431–1438PubMedCrossRef Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431–1438PubMedCrossRef
45.
Zurück zum Zitat Greenspan SL, Rosen HN, Parker RA (2000) Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 85:3537–3540PubMedCrossRef Greenspan SL, Rosen HN, Parker RA (2000) Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 85:3537–3540PubMedCrossRef
46.
Zurück zum Zitat Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056PubMedCrossRef Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056PubMedCrossRef
47.
Zurück zum Zitat Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258PubMedCrossRef Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258PubMedCrossRef
48.
Zurück zum Zitat Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D et al (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344–351PubMedCrossRef Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D et al (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344–351PubMedCrossRef
49.
Zurück zum Zitat Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42:832–836PubMedCrossRef Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42:832–836PubMedCrossRef
50.
Zurück zum Zitat Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798–803PubMedCrossRef Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798–803PubMedCrossRef
51.
Zurück zum Zitat Porter D, Pienowski D, Monier-Faugere MC, Mallluche H (2012) Difference in bone quality between high versus low turnover renal osteodystrophy. JASN (in press) Porter D, Pienowski D, Monier-Faugere MC, Mallluche H (2012) Difference in bone quality between high versus low turnover renal osteodystrophy. JASN (in press)
52.
Zurück zum Zitat Nickolas T, Cremers S, Zhang A, Stein E, Cohen A, Chauncey R, Nikkel L, Liu X, Boutroy S, Yin M, Staron R, Leonard M, McMahon D, Dworakowski E, and Shane E (2012) Biochemical markers of bone turnover discriminate fracture status in patients with pre-dialysis chronic kidney disease. JASN (in press) Nickolas T, Cremers S, Zhang A, Stein E, Cohen A, Chauncey R, Nikkel L, Liu X, Boutroy S, Yin M, Staron R, Leonard M, McMahon D, Dworakowski E, and Shane E (2012) Biochemical markers of bone turnover discriminate fracture status in patients with pre-dialysis chronic kidney disease. JASN (in press)
53.
Zurück zum Zitat Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475PubMedCrossRef Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475PubMedCrossRef
Metadaten
Titel
National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges
verfasst von
D. Bauer
J. Krege
N. Lane
E. Leary
C. Libanati
P. Miller
G. Myers
S. Silverman
H. W. Vesper
D. Lee
M. Payette
S. Randall
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 10/2012
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-012-2049-z

Weitere Artikel der Ausgabe 10/2012

Osteoporosis International 10/2012 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.